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Abstract
Background and objectives In primary FSGS, calcineurin inhibitors have primarily been studied in patients
deemed resistant to glucocorticoid therapy. Few data are available about their use early in the treatment of FSGS.
We sought to estimate the association between choice of therapy and ESRD in primary FSGS.
Design, setting, participants, & measurementsWe used an inception cohort of patients diagnosed with primary
FSGS by kidney biopsy between 1980 and 2012. Factors associatedwith initiation of therapywere identified using
logistic regression. Time–dependent Cox models were performed to compare time to ESRD between different
therapies.
Results In total, 458 patients were studied (173 treated with glucocorticoids alone, 90 treated with calcineurin
inhibitors with or without glucocorticoids, 12 treated with other agents, and 183 not treated with immunosup-
pressives). Tip lesion variant, absence of severe renal dysfunction (eGFR$30 ml/min per 1.73 m2), and hypo-
albuminemia were associated with a higher likelihood of exposure to any immunosuppressive therapy. Only tip
lesion was associated with initiation of glucocorticoids alone over calcineurin inhibitors. With adjusted Cox
regression, immunosuppressive therapy with glucocorticoids and/or calcineurin inhibitors was associated with
better renal survival than no immunosuppression (hazard ratio, 0.49; 95% confidence interval, 0.28 to 0.86).
Calcineurin inhibitors with or without glucocorticoids were not significantly associated with a lower likelihood
of ESRD compared with glucocorticoids alone (hazard ratio, 0.42; 95% confidence interval, 0.15 to 1.18).
Conclusions The use of immunosuppressive therapywith calcineurin inhibitors and/or glucocorticoids as part of
the early immunosuppressive regimen in primary FSGS was associated with improved renal outcome, but the
superiority of calcineurin inhibitors over glucocorticoids alone remained unproven.
Clin J Am Soc Nephrol 11: ccc–ccc, 2016. doi: 10.2215/CJN.07110615
Introduction
In adults, idiopathic FSGS represents the most com-
mon cause of primary nephrotic syndrome and the
most common cause of ESRD related to glomerular
disease (1,2). FSGS encompasses different histologic
variants, which differ in their epidemiology, clinical
course, and response to therapy (3).
Glucocorticoids have historically been used as a
first-line therapy in FSGS on the basis of retrospective
or uncontrolled prospective cohort studies (4–7);
however, no randomized, controlled trials were per-
formed to provide direct evidence of their efficacy in
preserving renal function. Furthermore, FSGS variant
was not taken into consideration in the choice of ther-
apy in these studies (8). The major randomized, con-
trolled trials in FSGS evaluated patients deemed
steroid resistant and used remission of proteinuria
as their primary end point (9,10). Although renal fail-
ure has been studied as a short–term secondary end
point in primary FSGS clinical trials, calcineurin in-
hibitors (CNIs; tacrolimus or cyclosporin) have not
been formally evaluated with respect to long–term
renal survival (ESRD) as a primary outcome, and
they were not compared with high-dose glucocor-
ticoids in a head-to-head randomized, controlled
trial.
This study was performed to determine the patient
and disease characteristics associated with choice of
therapy and estimate the association between choice
of early therapy and renal outcome (ESRD) in primary
idiopathic FSGS. This analysis tested the hypothesis
that the use of CNI therapy is associated with a de-
crease in the likelihood of ESRD after controlling for
other factors affecting renal survival.
Materials and Methods
Study Design and Population
All patients in the Glomerular Disease Collabora-
tive Network (GDCN) with biopsy-proven FSGS di-
agnosed between 1980 and 2012 were considered for
this inception cohort study. The GDCN FSGS registry
enrolls patients coming from 600 participating phy-
sicians in .250 clinics in eight states. Patients with
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a known secondary cause of FSGS, such as HIV, hepatitis
B or C, intravenous drug use, sickle cell disease, single
kidney, reflux nephropathy, or other GN, and transplant
recipients were excluded. Perihilar variant FSGS, believed
to be an “adaptive response to nephron loss or glomerular
hypertension” (11–16), was excluded. All biopsy specimens
had a minimum of five glomeruli assessed by light micros-
copy. FSGS variant was determined using the biopsy re-
port. Patients with any level of proteinuria were included
in the study to examine the full spectrum of FSGS. All
subjects provided written informed consent. This study
was approved by the University of North Carolina’s Insti-
tutional Review Board in agreement with the Declaration
of Helsinki.
Clinical Data and Definitions
Clinical and laboratory variables were extracted from
medical records from the time of renal biopsy to the last
available follow-up visit and/or initiation of RRT. Presence
of arterial hypertension was defined as systolic BP $140
mmHg and/or diastolic BP $90 mmHg for adults and
systolic and/or diastolic BP $95th percentile for age,
sex, and height for children (17). Quantification of protein-
uria was on the basis of either spot urinary protein-to-
creatinine ratio (Up/c) or 24-hour urine collection as reported
in the medical record. Complete remission was defined
as a reduction in proteinuria to #0.3 g/24 h (or 0.3 g/g
on Up/c) with #25% increase in serum creatinine. Partial
remission was defined as a reduction in proteinuria by
$50% to a level ,3.5 g/24 h (or 2.0 g/g on Up/c) and
.0.3 g/24 h or 0.3 g/g with stable renal function. Infor-
mation was also collected on immunosuppressive and an-
tihypertensive therapy. The primary outcome was ESRD
(eGFR,15 ml/min per 1.73 m2, dialysis, or transplanta-
tion). eGFR was calculated using the Modification of Diet
in Renal Disease Study group equation (18) for adults and
the Schwartz formula for children using height and serum
creatinine (19).
Immunomodulatory therapy was classified into three
groups: glucocorticoids alone, CNIs with or without gluco-
corticoids, and other immunosuppressive agents (e.g., aza-
thioprine, mycophenolate mofetil, and cyclophosphamide).
Exposure to therapy was defined as the first immunosup-
pressive treatment started after initial kidney biopsy, re-
gardless of the duration between biopsy and beginning of
immunosuppression. CNI therapy started within 3 months
of glucocorticoid initiation was considered early therapy.
Some patients were treated with a CNI and glucocorticoids
simultaneously, with the latter given at any dosage. Pa-
tients who were given glucocorticoids alone at a high
dose (1 mg/kg or $30 mg/d) were considered treated
with glucocorticoids. CNIs at any dosage were considered
as treatment with CNIs. Length of CNI therapy was de-
fined as the interval during which the drug was prescribed,
regardless of dosage. Length of glucocorticoid therapy was
defined as the interval during which the drug was pre-
scribed at high dose (1 mg/kg or $30 mg/d). Any treat-
ment with angiotensin–converting enzyme inhibitor,
angiotensin receptor blocker, or selective aldosterone
blocker was defined as renin-angiotensin-aldosterone sys-
tem inhibition.
Statistical Analyses
Normally distributed continuous variables were sum-
marized as means6SDs and compared using t tests. Var-
iables that were not normally distributed were summarized
as medians (interquartile ranges [IQRs]) and compared
with Mann–Whitney U tests. Chi-squared or Fisher exact
tests were used to compare categorical variables regarding
treatment and remission. A kernel density estimator was
used to approximate density from observations on the
length between renal biopsy and immunosuppression
initiation.
Identifying Factors Associated with Choice of Ther-
apy. To identify potentially important confounders in the
association between the choice of early immunomodula-
tory therapy and time to ESRD, factors associated with the
initiation of treatment with an immunomodulatory agent
at all (treated versus untreated) were investigated. Patients
who were prescribed high-dose glucocorticoids (1 mg/kg
or $30 mg/d), CNIs with or without glucocorticoids at
any dosage, or any other immunomodulatory agent were
considered treated, regardless of the duration of therapy.
A logistic regression was performed to identify factors as-
sociated with being prescribed any immunosuppressive
therapy (versus none).
Among those prescribed any immunosuppressive ther-
apy, another logistic regression model was fitted to
identify variables associated with having been prescribed
CNIs (with or without glucocorticoids) compared with
high-dose glucocorticoids alone. The 12 patients treated
with various other immunomodulatory agents were ex-
cluded from this analysis.
Modeling the Association between Choice of Therapy
and ESRD. Cox proportional hazards models were con-
structed to assess the association between initiation of
therapy and time to ESRD adjusted for potential con-
founders. Time zero was biopsy time. Time–dependent
Cox models in which the primary exposure (glucocorti-
coids alone or CNIs with or without glucocorticoids) was
allowed to change over time were used. The proportional
Figure 1. | Study flow diagram. CNI, calcineurin inhibitor.
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hazards assumption was tested using goodness of fit test-
ing (Schoenfeld residuals), log-log plots, and observed
versus expected plots. Renin-angiotensin-aldosterone
system inhibition was not included in models given
that a high proportion of patients on immunosuppres-
sion was exposed (.80%). Cox survival models were
also performed in adults only, and results are presented
separately.
Both the Kaplan–Meier survival method and Cox ad-
justed survival curves were used to visually evaluate the
relationship between treatment with immunosuppres-
sive therapy and primary end point (ESRD). Nelson–
Aalen adjusted survival curves were generated using
the following pattern of covariates: mean values for
age, baseline serum albumin, and eGFR among patients
treated with glucocorticoids alone or CNIs with or with-
out glucocorticoids; men; and not otherwise specified
(NOS) variant.
ManagingMissing Data. Missing values for race (4.2%),
baseline eGFR (2.8%), baseline 24-hour proteinuria (27.1%),
baseline serum albumin (17.7%), edema (15.7%), and pres-
ence of hypertension at baseline (15.7%) were imputed
using an iterative Markov chain Monte Carlo multiple
imputation technique (20 imputations) (20). The primary
exposure (immunosuppressive therapy or CNI treatment
with or without glucocorticoids glucocorticoids) was not
imputed in any analysis.
When proteinuria was measured using Up/c only
without concomitant 24-hour excretion quantification, the
missing 24-hour urine data were handled in two ways.
First, missing values were imputed as described above.
Second, missing 24-hour urine values were estimated from
the Up/c values using 1:1 and 1:1.5 conversion factors (21).
Cox regression models using both methods and both con-
version factors were fitted and compared with the hazard
ratio (HR) estimates.
Results for logistic regression models were expressed as
odds ratios (ORs) with 95% confidence intervals (95% CIs),
and results for Cox proportional hazards models were
expressed as HRs with 95% CIs. Statistical analyses were
performed using Stata 13 (StataCorp., College Station, TX).
All authors had access to the primary data; L.-P.L. per-
formed the statistical analysis.
Results
Patient Characteristics
Of 458 patients (84 children) with biopsy-proven FSGS,
183 received no immunosuppressive therapy, 173 received
glucocorticoids alone, 90 were treated with CNIs with or
without glucocorticoids (Figure 1, Table 1), and 12 were
treated with other immunomodulatory agents (six with
mycophenolate mofetil/glucocorticoids, four with cyclo-
phosphamide/glucocorticoids, one with azathioprine,
and one with adalimumab). Patients who did not receive
immunosuppressive therapy had lower median baseline
eGFR (43.8 ml/min per 1.73 m2; IQR, 27.2–69.9 ml/min
per 1.73 m2 versus 62.8 ml/min per 1.73 m2; IQR, 41.7–
85.7 ml/min per 1.73 m2; P,0.001) and lower median
baseline 24-hour proteinuria (3.8 g/d; IQR, 2.4–6.6 g/d ver-
sus 6.0 g/d; IQR, 3.5–12.0 g/d; P,0.001) than those who
received immunosuppressive therapy.
Immunosuppression
Median time to initiation of high-dose glucocorticoids
after biopsy was 0.3 months (IQR, 0.03–0.8 months), and
median time to initiation of CNI therapy after biopsy was
0.7 months (IQR, 0.1–3.0 months). Median duration of
high–dose glucocorticoid therapy was 3.0 months (IQR,
1.5–5.9 months). Among those treated with CNIs, 75%
started CNIs within 3 months after kidney biopsy (Figure
2), and only 28 (31.1%) patients were given CNIs alone.
CNI treatment had a median duration of 19.6 months
(IQR, 6.5–34.8 months).
Factors Associated with Exposure to Immunosuppressive
Therapy
The factors significantly associated with immunosuppres-
sive treatment are summarized in Table 2. The odds of re-
ceiving immunosuppression were significantly lower among
patients with eGFR,30 ml/min per 1.73 m2 at baseline than
in those with an eGFR$30 ml/min per 1.73 m2 (OR, 0.53;
95% CI, 0.29 to 0.99) and those with advancing age (OR, 0.82
for each 10-year increment; 95% CI, 0.74 to 1). Lower base-
line serum albumin was associated with a higher likelihood
of receiving immunosuppressive therapy (OR, 2.22 for each
1 g/dl decrease; 95% CI, 1.59 to 3.13). Patients with a tip
lesion were three times more likely to be treated with im-
munosuppressives than those with the NOS FSGS variant
(OR, 3.00; 95% CI, 1.23 to 7.32) (Supplemental Table 1).
Factors Associated with Choice of Immunosuppressive
Therapy
The multivariable logistic regression model (including
age, race, and baseline albuminemia and proteinuria) iden-
tified only histologic variant as independently associated
with the odds of being treated with CNIs; compared with
FSGS NOS, tip lesion FSGS was associated with signifi-
cantly lower likelihood of treatment with CNI (OR, 0.17;
95% CI, 0.05 to 0.53).
Immunosuppressive Therapy and Time to ESRD
Any Immunosuppression Versus None. Exposure to
any immunosuppressive therapy (versus none) was asso-
ciated with better renal survival in both unadjusted and
Figure 2. | Probability density function of time length between renal
biopsy and immunosuppression therapy. CNI, calcineurin inhibitor.
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adjusted Cox survival models (Table 3). The crude cumu-
lative probabilities of being ESRD free at 1, 2, and 5 years
were 94.4% (204 at risk), 87.9% (154 at risk), and 67.4% (59
at risk) for those treated with any immunosuppressive
therapy compared with 87.8% (125 at risk), 78.2% (90 at
risk), and 60.0% (26 at risk) for patients not treated with
immunosuppressive therapy (Figure 3A). Compared with
no treatment, treatment with any immunosuppression was
associated with significantly lower hazards of ESRD (HR,
0.49; 95% CI, 0.28 to 0.86). A baseline eGFR ,30 ml/min
per 1.73 m2 was associated with higher hazards of ESRD
(HR, 4.28; 95% CI, 2.81 to 6.48). Among adults only, treat-
ment with any immunosuppression was also associated
with significantly lower hazards of ESRD (HR, 0.43; 95%
CI, 0.21 to 0.86).
CNIs Versus Glucocorticoids Alone. Compared with
those treated with glucocorticoids alone, the adjusted risk
of ESRD was not statistically significantly lower among
Table 3. Factors associated with ESRD by immunosuppression status
Variables Hazard Ratio 95% Confidence Interval
Unadjusted
Immunosuppression
None 1
CNIs with or without glucocorticoids or glucocorticoids alone 0.50 0.29 to 0.87
Adjusteda
Immunosuppression
None 1
CNIs with or without glucocorticoids or glucocorticoids alone 0.49 0.28 to 0.86
Age per 1-yr increase 1.00 0.99 to 1.01
Men 1.15 0.76 to 1.73
FSGS variant
NOS 1
Tip 0.21 0.09 to 0.48
Collapsing 1.71 0.99 to 2.95
Baseline eGFR ,30 ml/min per 1.73 m2 4.28 2.81 to 6.48
Baseline proteinuria $3.5 g/d 1.25 0.68 to 2.29
Serum albumin at biopsy per 1 g/dl higher 0.69 0.53 to 0.90
Hypertension at baseline 1.33 0.81 to 2.20
Adjusted (adults only)b
Immunosuppression
None 1
CNIs with or without glucocorticoids or glucocorticoids alone 0.43 0.21 to 0.86
CNI, calcineurin inhibitor; NOS, not otherwise specified.
aCox regression adjusted for immunosuppression, age, sex, black race, FSGS variant, and baseline eGFR, proteinuria, serum albumin,
and hypertension.
bCox regression in adult patients only adjusted for immunosuppression, age, sex, black race, FSGS variant, and baseline eGFR, pro-
teinuria, serum albumin, and hypertension.
Table 2. Factors associated with treatment with immunosuppressive therapy
Variables
Univariate Multivariate
OR 95% CI OR 95% CI
Age at biopsy per 10-yr higher 0.82 0.74 to 0.90 0.82 0.74 to 1.00
Men 0.96 0.66 to 1.40 1.28 0.77 to 2.13
Black race 1.02 0.70 to 1.50 0.87 0.50 to 1.50
FSGS variant
NOS 1.00 1.00
Tip 4.62 2.27 to 9.37 3.00 1.23 to 7.32
Collapsing 1.79 1.01 to 3.19 1.19 0.53 to 2.68
Baseline eGFR ,30 ml/min per 1.73 m2 0.42 0.26 to 0.67 0.53 0.29 to 0.99
Baseline proteinuria $3.5 g/d 2.03 1.32 to 3.13 1.04 0.56 to 1.93
Serum albumin at biopsy per 1 g/dl lower 2.44 1.92 to 3.03 2.22 1.59 to 3.13
Edema at baseline 2.59 1.69 to 3.96 1.42 0.81 to 2.49
Hypertension at baseline 0.82 0.54 to 1.25 0.92 0.52 to 1.64
OR, odds ratio; 95% CI, 95% confidence interval; NOS, not otherwise specified.
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those treated with CNIs (HR, 0.42; 95% CI, 0.15 to 1.18)
(Table 4). Adjusted survival curves suggested a trend to-
ward better long–term renal survival associated with treat-
ment including CNIs than that with glucocorticoids alone
(Figure 4). A baseline eGFR ,30 ml/min per 1.73 m2 was
also associated with higher hazards of ESRD (HR, 2.61;
95% CI, 1.37 to 4.96) among treated patients. An additional
Cox regression model, including proteinuria at baseline in
lieu of baseline albuminemia as a covariate, showed a sim-
ilar nonstatistically significant lower risk of ESRD associ-
ated with CNIs compared with glucocorticoids alone (HR,
0.50; 95% CI, 0.18 to 1.44). In this model, each 1-g/d incre-
ment in baseline proteinuria was associated with a higher
likelihood of ESRD (HR, 1.06; 95% CI, 1.02 to 1.11). Among
treated adults only, treatment with CNIs with or without
glucocorticoids was not associated with significantly lower
hazards of ESRD (HR, 0.40; 95% CI, 0.09 to 1.90).
Sensitivity Analyses for Proteinuria at Baseline
Additional multivariable Cox regression models were
constructed, in which missing 24-hour proteinuria data were
converted from Up/c (using 1:1 and 1:1.5 conversion factors)
rather than imputed. The adjusted HRs (time to ESRD)
obtained from these models for treatment with immuno-
suppressive therapy were of similar magnitude and signif-
icance (HR, 0.47; 95% CI, 0.27 to 0.84 for 1:1 conversion; HR,
0.46; 95% CI, 0.26 to 0.83 for 1:1.5 conversion) to those
estimated when missing 24-hour proteinuria values were
imputed (HR, 0.49; 95% CI, 0.28 to 0.86).
Immunosuppressive Therapy and Remission
Among 163 patients with nephrotic-range proteinuria at
baseline and documented proteinuria quantification dur-
ing follow-up, 66 (40.5%) reached partial remission, and 36
(22.1%) reached complete remission. A high proportion of
patients who were nephrotic (46.6%) had incomplete
documentation of proteinuria during the course of disease.
Exposure to immunosuppressive therapy was not signif-
icantly associated with remission in proteinuria, with 26
(39.4%) patients exposed to any immunosuppression
reaching complete or partial remission compared with
eight (28.6%) patients unexposed reaching complete or
partial remission (P=0.32).
Discussion
Primary FSGS is a heterogeneous entity for which
evidence of effective immunosuppressive therapy is lim-
ited. Current recommendations on the use of glucocorti-
coids as first-line treatment are on the basis of retrospective
studies using a variety of regimens (4–7). However, high–
dose glucocorticoid therapy is associated with a number of
adverse effects (22). The use of CNIs in primary FSGS is on
the basis of clinical trials in patients deemed resistant to
glucocorticoid therapy (23). No clinical trial has assessed
CNIs as first–line immunosuppressive therapy in primary
FSGS or directly compared CNI treatment with glucocor-
ticoids alone. This study describes the association between
choice of early therapy (including CNIs) and renal survival
(ESRD) in primary FSGS, while adjusting for the most im-
portant potential confounders in this relationship between
treatment and renal outcome.
Several patient and disease characteristics were poten-
tially associated with both initiation of therapy and renal
outcome. To assure the inclusion of the most important
ones in the analyses, factors associated with a decision to
treat with immunosuppressives were first identified. The
results showed that the initiation of immunosuppressive
therapy was associated with FSGS variant, baseline renal
function, and severity of nephrotic syndrome as indi-
cated by the degree of hypoalbuminemia. Also, factors
associated with the choice of early immunosuppressive
therapy (glucocorticoids versus CNIs) were determined.
This study identified only the presence of tip lesion as an
independent factor favoring glucocorticoids alone over
CNIs.
The association between exposure to any immunosup-
pressive therapy and ESRD was subsequently examined
while considering important confounders. This study sup-
ports a role for immunosuppressive therapy with glucocor-
ticoids and/or CNIs to positively influence renal survival. It
also suggests that early treatment of patients with FSGS
with CNIs combined with glucocorticoids may be associ-
ated with an improved renal survival compared with no
immunosuppressive therapy.
The association between CNIs (with or without gluco-
corticoids) and time to ESRD among patients treated with
immunosuppressive therapy was next assessed. Although
not statistically significant, the results suggest that early
introduction of immunosuppressives, including CNIs, may
be associated with a lower likelihood of ESRD compared
with treatment with glucocorticoids alone after controlling
Figure 3. | Kaplan–Meier (K-M) curves of time to ESRD by immu-
nosuppression status. (A) For all patients; (B) for adults only.
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for variables known to affect renal outcome (HR, 0.42; 95%
CI, 0.15 to 1.18).
Since the 1999 landmark study by Cattran et al. (9),
which reported an increased likelihood of remission of
proteinuria in steroid-resistant patients treated with
CNIs, clinicians may have been more likely to prescribe
CNIs as a first-choice treatment. Indeed, .10% of patients
on immunosuppression in our cohort were exposed to
CNIs alone. Although several patient and disease
characteristics seemed to influence selection of the immu-
nomodulatory agent on univariate analyses, a significant
independent association was only found between tip le-
sion FSGS and glucocorticoid therapy alone. Tip lesion
FSGS has been described to share common clinical features
with minimal change disease and respond promptly to
high-dose glucocorticoids (24).
This study supports a potential role for including CNIs
in the early treatment of primary FSGS but is not able to
prove superiority of CNIs with or without glucocorti-
coids over glucocorticoids alone. Combinations of im-
munosuppressive agents were frequently used, and few
patients were exposed to CNIs alone (n=28). Because the
majority of patients receiving CNIs were also treated
with glucocorticoids, the ability to distinguish the bene-
fits of CNIs alone from the combination of CNIs and
high-dose glucocorticoids is limited because of lack of
power.
The findings are consistent with previously reported
clinical findings. Baseline level of proteinuria was pre-
viously shown to have prognostic significance (25,26). It
showed that baseline proteinuria was also predictive of re-
nal survival among patients treated with immunosuppres-
sive therapy. It was not possible to examine the effect of
remission in proteinuria on renal outcome because of in-
complete documentation of proteinuria at fixed intervals.
Moreover, incompleteness of data on follow-up proteinuria
precluded the accurate description of the response to im-
munosuppressive therapy. As expected and previously
shown, severe renal dysfunction at baseline (eGFR,
30 ml/min per 1.73 m2) was predictive of poorer renal
survival (27,28).
Figure 4. | Predicted ESRD–free Nelson–Aalen curves: these curves
are predicted for the adjusted Cox time–dependent model. Out-
comes for the glucocorticoids alone and calcineurin inhibitors (CNIs)
with or without glucocorticoids groups are computed at the mean
(age, men, not otherwise specified variant, baseline serum albumin,
and eGFR).
Table 4. Factors associated with ESRD among treated patients
Variables Hazard Ratio 95% Confidence Interval
Unadjusted
Immunosuppressive therapy
Glucocorticoids 1.00
CNIs with or without glucocorticoids 0.60 0.21 to 1.70
Adjusteda
Immunosuppressive therapy
Glucocorticoids 1.00
CNIs with or without glucocorticoids 0.42 0.15 to 1.18
Age per 1-yr increase 1.00 0.99 to 1.02
Men 1.00 0.56 to 1.76
FSGS variant
NOS 1.00
Tip 0.14 0.04 to 0.47
Collapsing 0.98 0.48 to 2.00
Baseline eGFR ,30 ml/min per 1.73 m2 2.61 1.37 to 4.96
Serum albumin at biopsy per 1 g/dl higher 0.55 0.39 to 0.78
Adjusted (adults only)b
Immunosuppressive therapy
Glucocorticoids 1.00
CNIs with or without glucocorticoids 0.40 0.09 to 1.90
CNI, calcineurin inhibitor; NOS, not otherwise specified.
aCox regression adjusted for immunosuppression, age, sex, black race, FSGS variant, and baseline eGFR and serum albumin; baseline
hypertension was not predictive of renal survival by univariate analysis.
bCox regression in adult patients only adjusted for immunosuppression, age, FSGS variant, and baseline eGFR and serum albumin.
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Severe hypoalbuminemia has been shown to be associ-
ated with complications of the nephrotic syndrome, such as
thromboembolism (29–31). However, the value of hypoal-
buminemia as a predictor of renal outcome in primary
FSGS had not been previously described. The results of
this analysis suggest that baseline serum albumin is asso-
ciated with renal survival. However, the effect of recovery
from severe hypoalbuminemia on renal survival has not
been examined with this study design. It was also not pos-
sible to include both baseline albuminemia and proteinuria
in the same Cox regression model when comparing CNIs
(with or without glucocorticoids) with glucocorticoids
alone because of the small number of renal failure events,
resulting in power limitations.
This study has some limitations inherent to its retro-
spective nature. These include a lack of uniform treatment
protocol and systematic laboratory tests at fixed intervals
and variable follow-up intervals. As a result, some vari-
ables of interest had a significant proportion of missing
values, impeding their use in statistical models with
multiple imputations. This could lead to residual con-
founding. For example, presence of obesity (high body mass
index) could influence the initiation of immunosuppres-
sive therapy by favoring steroid-sparing agents to avoid
glucocorticoid-induced diabetes and modify disease tra-
jectory by adding a superimposed glomerular injury. For
the balance of the variables, missing values were handled
using multiple imputation, which provides less biased
estimates than complete patient analysis (20). The survival
model also has limitations by not perfectly adjusting for
all potential confounders. Some patients, especially chil-
dren, may have been exposed to immunosuppression be-
fore renal biopsy. The results show, however, similar
finding when restricting the survival analyses to adults
only. Unaccounted prebiopsy treatment with glucocorti-
coids alone is not likely to have influenced our results
significantly, because children ,10 years old at the time
of renal biopsy accounted for only 5% of the total cohort.
Use of propensity score methods was considered to ac-
count for confounding by variables associated with clinical
choice to initiate treatment (32). However, creation of a pro-
pensity score–matched cohort would have required the ex-
clusion of numerous subjects from our analysis for those
not paired, which would have considerably reduced al-
ready limited statistical power.
In conclusion, despite the fact that patients treated with
immunosuppressives tended to have evidence of more
severe nephrotic syndrome than those who were untreated,
this study showed a significant association between treat-
ment with immunosuppressive therapy and better renal
survival. This observation could not, however, establish
differences in efficacy between treatment modalities.
Whether the early use of CNIs alone or in addition to
glucocorticoids is of benefit in preserving renal function in
patients with FSGS should be formally tested in a pro-
spective randomized clinical trial.
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